Our business, financial condition, results of operations and prospects may have changed since that date.Information contained in our website does not constitute part of this prospectus.We use MatBA®, UroGenRA™, UGenRA™, FHACT™, FReCAD™, Expand DX™, Select One®, Summation™ Report and the Cancer Genetics logo as trademarks in the United States and elsewhere.
To achieve this objective, we intend to:•continue investing in our portfolio by developing and commercializing additional proprietary genomic tests and services;•continue our focus on rapidly applying genomic research to routine clinical cancer diagnostics (translational oncology) and drive innovation and cost
efficiency in diagnostics by developing next generation sequencing offerings through our joint venture with Mayo Clinic;•enhance our efforts to partner with community hospitals;•increase our focus on providing biopharmaceutical companies and clinical research organizations with our proprietary genomic tests and services through
We are also focused on developing relationships with biopharmaceutical companies and clinical research organizations who can leverage our proprietary genomic tests and services to increase efficiency of their clinical trials.-4-Table of ContentsRisks That We FaceAn investment in our common stock involves a high degree of risk.
sustained profitability;•our business depends upon our ability to increase sales of our laboratory tests and services;•we need additional financing, through this offering or otherwise, to meet our liquidity needs, including approximately $6.0 million to repay
outstanding indebtedness due on April 1, 2014 and depending on the results of this offering, we may need additional capital to fund our operations thereafter;•we need to clinically validate our pipeline of microarray tests currently in development;•our business depends on our ability to continually develop and commercialize novel and innovative diagnostic cancer tests and services;•our business depends on executing on our sales and marketing strategy for our proprietary tests and gaining acceptance of our tests in the market;•our business depends on satisfying United States (including FDA) and international regulatory requirements with respect to our tests and services and
We currently expect to use the net proceeds from this offering as follows:•$2.0 million to fund our 2014 contributions to our joint venture with Mayo;•approximately $15.0 million to hire additional sales and marketing personnel and support increased sales and marketing activities;•approximately $5.0 million to fund further research and development, potential regulatory submissions and the potential commercial launch of our
which was the last reported sale price of our common stock on The NASDAQ Capital Market on October 16, 2013.-7-Table of ContentsSUMMARY CONSOLIDATED FINANCIAL DATAThe following table sets forth our summary statement of operations data for the years ended December 31, 2012, 2011 and 2010 derived
This could cause the trading price of our common stock to decline and you could lose all or part of your investment.Risks Relating to Our Financial Condition and Capital RequirementsWe are an early stage company with a history of net losses; we expect to incur net losses in the future, and we may never achieve sustained profitability.We have historically incurred substantial net losses.
sales and marketing and research and development activities are forward-looking statements and involve risks and uncertainties.Depending on the results of this offering, we may also need to raise additional capital to expand our business to meet our long-term
For further discussion of our liquidity requirements as they relate to our long-term plans, see the section entitled “Liquidity and Capital Resources—Capital Resources and Expenditure Requirements”.Risks Relating to Our Business and StrategyIf we are unable to increase sales of our laboratory tests and services or to successfully develop and commercialize other proprietary tests, our revenues will be insufficient for us to achieve
efforts of the joint venture do not result in commercially successful tests or services, it will have an adverse effect on our business, financial condition and results of operations.If we are unable to obtain regulatory clearance or approvals in the United States, if we experience delays in receiving clearance or approvals, or if we do not gain acceptance from other
operations to fund working capital, capital expenditures or other general corporate purposes;•limit our flexibility in planning for, or reacting to, changes in our business and industry;•place us at a disadvantage compared to competitors that may have proportionately less debt; and•increase our cost of borrowing.We will need to raise additional capital, through this offering or otherwise, to repay indebtedness, to fund our existing operations and to develop and commercialize new tests and technologies and
offering or otherwise, to expand our business to meet our long-term business objectives, including to:•increase our sales and marketing efforts to drive market adoption and address competitive developments;•fund development and marketing efforts of any future tests;•further expand our clinical laboratory operations;-14-Table of Contents•expand our technologies into other types of cancer;•acquire, license or invest in technologies;•acquire or invest in complementary businesses or assets;•fund our subsequent contributions of up to $4.0 million to our joint venture with Mayo if our joint venture with Mayo achieves certain operational
milestones; and•finance capital expenditures and general and administrative expenses.Our present and future funding requirements will depend on many factors, including:•our ability to achieve revenue growth;•our rate of progress in establishing reimbursement arrangements with domestic and international third-party payors;•the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts;•our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of and reimbursement for our microarray
“CE Marking”, a conformity mark which is required to market in vitro diagnostic medical devices in the European Economic Area and which is broadly accepted in other international markets;•difficulties in managing foreign operations;•complexities associated with managing multiple payor-reimbursement regimes or self-pay systems;•logistics and regulations associated with shipping tissue samples, including infrastructure conditions and transportation delays;•limits on our ability to penetrate international markets if our diagnostic tests cannot be processed by an appropriately qualified local laboratory;•financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to foreign currency
The factors that may cause the market price of our common stock to fluctuate include, but are not limited to:•progress, or lack of progress, in developing and commercializing our proprietary tests;•favorable or unfavorable decisions about our tests or services from government regulators, insurance companies or other third-party payors;•our ability to recruit and retain qualified regulatory and research and development personnel;•changes in investors’ and securities analysts’ perception of the business risks and conditions of our business;•changes in our relationship with key collaborators;-35-Table of Contents•changes in the market valuation or earnings of our competitors or companies viewed as similar to us;•changes in key personnel;•depth of the trading market in our common stock;•termination of the lock-up agreements or other restrictions on the ability of persons who held our stock prior to our initial public offering to sell